Recommendation of the President – Trulance (plecanatide)
On 8 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 3/2026 on the validity of issuing approvals for the reimbursement of the medicinal product Trulance (plecanatide) for the indication: constipation in patients with pelvic floor dyssynergia